<PAGE>
-------------------------
OMB APPROVAL
-------------------------
OMB Number: 3235-0167
Expires: October 31, 2001
Estimated average burden
hours per response...1.50
-------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-22383
-----------------
Transcend Therapeutics, Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
738 Main Street, Waltham, Massachusetts 02451
- --------------------------------------------------------------------------------
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)
Common Stock, par value $.01 per share
- --------------------------------------------------------------------------------
(Title of each class of securities covered by this Form)
None
- --------------------------------------------------------------------------------
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule l2g-4(a)(1)(i) [X]* Rule l2h-3(b)(l)(i) [_]
Rule l2g-4(a)(1)(ii) [_] Rule 12h-3(b)(1)(ii) [_]
Rule l2g-4(a)(2)(i) [_] Rule l2h-3(b)(2)(i) [_]
Rule l2g-4(a)(2)(ii) [X]* Rule l2h-3(b)(2)(ii) [_]
Rule l5d-6 [_]
*Transcend Therapeutics, Inc., a Delaware corporation, was merged with and
into KVTT Acquisition Corporation, a Delaware corporation and wholly-owned
subsidiary of KeraVision, Inc., a Delaware corporation, effective as of May 28,
1999.
Approximate number of holders of record as of the certification or notice
date: One (1)
-------
Pursuant to the requirements of the Securities Exchange Act of 1934,
Transcend Therapeutics, Inc. has caused this certification/notice to be signed
on its behalf by the undersigned duly authorized person.
Date: June 4, 1999 By: /s/ Thomas M. Loarie
--- ---------------------------------------------------------
Thomas M. Loarie, President and Chief Executive Officer
Instruction: This form is required by Rules 12g-4, 12h-3 and l5d-6 of the
General Rules and Regulations under the Securities Exchange Act of 1934. The
registrant shall file with the Commission three copies of Form 15, one of which
shall be manually signed. It may be signed by an officer of the registrant, by
counsel or by any other duly authorized person. The name and title of the
person signing the form shall be typed or printed under the signature.
Potential persons who are to respond to the collection of
information contained in this form are not required to respond
SEC 2069 (3-99) unless the form displays a currently valid OMB control number.
